NanoHybrids Launches Revolutionary Contrast Agent to Measure EPR Effect at 2018 SPIE BiOS Expo

NanoHybrids, announces the launch of PAtrace, a proprietary nanoparticle that provides high resolution visualization and verification of the enhanced permeability and retention (EPR) effect in heterogeneous tumor models. PAtrace is being launched at the 2018 SPIE BioS Expo. - January 29, 2018

Targeted Hyperthermia Treatment Accepted for Full Characterization at the Frederick National Laboratory for Cancer Research

Siva Therapeutics in partnership with NanoHybrids have teamed to develop and manufacture gold nanoparticles for treating cancer with hyperthermia. The nanoparticle treatment was submitted to the Frederick National Laboratory for Cancer Research and has passed the first stages in the Nanotechnology Characterization Laboratory, which helps pave the way for regulatory review of nanotechnologies intended for cancer therapies and diagnostics. - December 15, 2017

NanoHybrids Inc. Awarded NIH Grant to Advance Nanoparticle Enabled Photodynamic Therapy for Oral Cancer

NanoHybrids Inc. has been awarded $300,000 by the National Cancer Institute of the National Institutes of Health (NIH) through the Small Business Technology Transfer (STTR) program to enhance the therapeutic efficacy of photodynamic therapy (PDT) in oral cancers. - December 15, 2017

NanoHybrids to Sponsor Gold Nanoparticles for Selected Research Proposals

For a limited time, NanoHybrids is accepting applications for a chance to win a supply of their top Gold Nanoparticles to enhance imaging project results. - June 10, 2016

Nanohybrids Expands Nanoparticle Product Line with Launch of 30 nm Gold Nanospheres

NanoHybrids releases 30 nm spherical gold nanoparticles. With this product launch NanoHybrids now offers a full complement of NanoSphere products ranging in diameter from 5 nm to 60 nm. Various surface coatings are also available to suit a wide range of application needs. - April 20, 2016

NSF Funds NanoHybrids’ Improved Chemotherapy Delivery Platform

NSF SBIR grant to be used to advance nanoparticle platform for safe, effective, and controlled cancer drug delivery. - March 16, 2016

NanoHybrids Receives Grant Funding to Develop Breakthrough Technology in Cancer Detection and Diagnosis

NanoHybrids receives $225,000 from the National Cancer Institute (NCI) to develop breakthrough immunohistochemistry (IHC) technology. - January 10, 2016

NanoHybrids Launches Gold Nanoparticles Custom Designed to Improve Lateral Flow Quality and Reproducibility

Careful selection of indicator particles is absolutely critical to the performance of any lateral flow assay. NanoHybrids’ new line of monodisperse gold nanoparticles can enable the development of lateral flow assays that meet the highest specifications of the industry, particularly with respect to sensitivity and reproducibility. - August 16, 2015

NanoHybrids Enters into Distribution Agreement with Eikonix

NanoHybrids Inc, a biotechnology company based in Austin, Texas, and Eikonix, UK, a distributor of imaging systems and contrast agents announced today that they have entered into an agreement that adds NanoHybrids’ premium gold nanoparticles to Eikonix's extensive offering of scientific... - July 23, 2015

NanoHybrids Publishes White Paper on "Make vs Buy" Gold Nanoparticles

“Should we try and make our own gold nanoparticles or buy them from a supplier?” This white paper approaches the question objectively to see which customers could benefit the most from buying gold nanoparticles instead of making them in house. - November 26, 2014

NanoHybrids Receives Funding to Develop Molecular Imaging Agent for Atherosclerosis

NanoHybrids, Inc., an Austin-based, emerging biotech company developing nanotechnology-based clinical and pre-clinical solutions, was recently awarded a Small Business Innovation Research (SBIR) contract grant to develop a targeted biocompatible imaging contrast agent that will help detect high risk atherosclerotic plaques. - October 25, 2014

NanoHybrids Inc. Launches Its First Product Line of Imaging Contrast Agents

NanoHybrids develops nano-sized contrast agents that can enhance biomedical imaging techniques by interacting specifically with diseased cells and allowing for real time imaging of functional biology. These products can potentially be employed in a wide variety of applications including optical biomedical imaging, microscopy, molecular diagnostics and theranostic approaches. - March 07, 2014

Press Releases 1 - 12 of 12